Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial-Reference-Cited by-同舟云学术

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial

Published:2022-06-16 Issue:3 Volume:11 Page:1409-1425
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Ferreira Joaquim J.,Poewe Werner,Rascol Olivier,Stocchi Fabrizio,Antonini Angelo,Moreira Joana,Pereira Ana,Rocha José-Francisco,Soares-da-Silva Patrício

Funder

Bial

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-022-00371-7.pdf

Reference43 articles.

1. Greenland JC, Barker RA. Chapter 6: the differential diagnosis of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s disease: pathogenesis and clinical aspects [Internet]. Brisbane: Codon; 2018.

2. Lebouvier T, Chaumette T, Paillusson S, et al. The second brain and Parkinson's disease. Eur J Neurosci. 2009;30(5):735–41. https://doi.org/10.1111/j.1460-9568.2009.06873.x.

3. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53. https://doi.org/10.1016/S1474-4422(18)30295-3.